Novartis, ptc therapeutics and Huntington's disease

Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing Phase II data in amyotrophic lateral sclerosis.
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in development, regulatory and sales milestones. NVS will also share profits in the United States (40% PTC and 60% Novartis) and pay tiered royalties on ex-US sales.
Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological disorder called Huntington's disease, sending the U.S.-based biotech's shares up about 14% on Monday.
Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping the biotech bounce quickly back from disappointing data on another program.
Novartis wagers billions of dollars on PTC Huntington’s drug
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.
PTC Therapeutics enters global license, collaboration agreement with Novartis
PTC Therapeutics (PTCT) announced the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals
PTC Therapeutics signs up to $2.9 billion licensing deal with Novartis
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug for a rare neurological disorder, sending its shares up 20% in premarket trading on Monday.
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Key Takeaways Shares of PTC Therapeutics soared Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.The deal gives Novartis global development,
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate
PTC Therapeutics (PTCT) signed a licensing deal with Novartis (NVS) unit Novartis Pharmaceuticals worth up to $2.9 billion for PTC518, its candidate treatment for Huntington's disease, the companies said in separate Monday statements.
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
Novartis to pay $1 billion upfront to license Huntington’s drug from PTC
Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC Therapeutics.
Hosted on MSN1d
Beta-Blockers Tied to Delayed Huntington's Disease Progression
The findings suggest that beta-blockers and other drugs that help restore balance to the autonomic nervous system may have ...
News Medical on MSN5h
Heart medication may slow the progression of Huntington's disease
Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
Common heart drug shows promise for Huntington’s disease
Common symptoms of Huntington's include uncontrolled movements like jerking and twitching, loss of coordination, difficulty ...
Deccan Chronicle8d
Huntington’s Disease: The Genetic Brain Decay
Huntington’s disease poses a threat to the brain—the core governing system of sensation, intellectual ability, nerve-related ...
labiotech13d
Huntington’s disease: a therapeutic field on a bumpy ride
After years of setbacks, biotechs are advancing treatments for Huntington’s disease, offering new hope as clinical studies ...
Psychology Today6d
How Huntington's Disease Helped Me Find My Magic
The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...
Common heart drug may slow progression of Huntington's disease
A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa ...